Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H23NO3.ClH |
Molecular Weight | 301.809 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
InChI
InChIKey=COAJXCLTPGGDAJ-UHFFFAOYSA-N
InChI=1S/C15H23NO3.ClH/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3;/h4-8,12-13,16-17H,1,9-11H2,2-3H3;1H
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6356863/Curator's Comment: Description was created based on several sources, including:
https://www.medicines.org.uk/emc/PIL.27982.latest.pdf
https://www.ncbi.nlm.nih.gov/pubmed/6344036
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6356863/
Curator's Comment: Description was created based on several sources, including:
https://www.medicines.org.uk/emc/PIL.27982.latest.pdf
https://www.ncbi.nlm.nih.gov/pubmed/6344036
Oxprenolol is clinically a well-established beta blocker that shares with other members of this group the ability to control a variety of disorders, in particular, hypertension and angina. Pharmacologically it is a nonselective beta blocker that possesses partial agonist activity (intrinsic sympathomimetic activity). Pharmacokinetically, oxprenolol behaves as a moderately lipophilic agent. Oxprenolol undergoes first pass metabolism with only 30% of an oral dose reaching the systemic circulation. The drug is approximately 80% protein bound and is eliminated primarily by glucuronidation in the liver. Less than 4% of oxprenolol is excreted unchanged in the urine. Oxprenolol may reduce the heart rate and prolong the effective and functional atrioventricular nodal refractory period. Oxprenolol has less negative inotropic and chronotropic effects than propranolol. Plasma renin activity is reduced; however, changes in plasma aldosterone level are not significant. Long term metabolic effects require further study. Chest pain (angina), high blood pressure (hypertension), irregular heart beats and anxiety are indications for Oxprenolol usage. To date Oxprenolol is discontinued by FDA.
Originator
Sources: Drug Discovery: A History. W. Sneader. John Wiley & Sons, 2005 pp 468
Curator's Comment: https://books.google.ru/books?id=Cb6BOkj9fK4C&pg=PA193&lpg=PA193&dq=Oxprenolol+first+discovered&source=bl&ots=NOemB0BehV&sig=ozflVDgEzprG_g-hgUfTYdJeoPw&hl=ru&sa=X&ved=0ahUKEwiv1pLbl6jQAhUHiCwKHTGTDusQ6AEIIzAB#v=onepage&q=Oxprenolol&f=false
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094118 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08318 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date1983 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date1983 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date1983 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date1983 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.7 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-(-)-OXPRENOLOL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
73.1 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-(+)-OXPRENOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
108.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-(-)-OXPRENOLOL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
111.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-(+)-OXPRENOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, intravenous Highest studied dose |
healthy, 21 - 29 years n = 6 Health Status: healthy Age Group: 21 - 29 years Sex: M+F Population Size: 6 Sources: |
|
480 mg 1 times / day multiple, oral Studied dose Dose: 480 mg, 1 times / day Route: oral Route: multiple Dose: 480 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (severe, 1 patient) Sources: |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Weakness, Headache... AEs leading to discontinuation/dose reduction: Weakness (6 patients) Sources: Headache (6 patients) Malaise (6 patients) Fatigue (6 patients) Bad dreams (6 patients) Fluid retention (1 patient) |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Weakness, Headache... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Sources: Headache (2 patients) Malaise (2 patients) Fatigue (2 patients) Bad dreams (2 patients) Fluid retention (1 patient) |
160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy n = 1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | severe, 1 patient Disc. AE |
480 mg 1 times / day multiple, oral Studied dose Dose: 480 mg, 1 times / day Route: oral Route: multiple Dose: 480 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fluid retention | 1 patient Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Bad dreams | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fatigue | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Headache | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Malaise | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Weakness | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fluid retention | 1 patient Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Bad dreams | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fatigue | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Headache | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Malaise | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Weakness | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Use of oxprenolol in cardiac arrhythmias associated with acute myocardial ischaemia. | 1971 Jan 30 |
|
Idioventricular tachycardia elicited by the combined administration of trasicor and lidocain. | 1972 |
|
Prevention of isoproterenol-induced cardiac hypertrophy by beta-blocking agents in the rat. | 1976 |
|
Effect of beta-blockade during bowling competitions. | 1976 Dec |
|
Inappropriate antihypertensive therapy in the elderly. | 1976 Dec 18 |
|
[Experimental anti-arrhythmic effects of a new beta-adrenergic receptor blocking agent, dl-l-(tert. butylamino)-3-[(2-propinyloxy)phenoxy]2-propanol hydrochloride (dl Kö 1400-Cl)]. | 1976 Jul |
|
Severe hypertension produced by interaction of phenylpropanolamine with methyldopa and oxprenolol. | 1976 Jul 31 |
|
Raynaud's phenomenon as side effect of beta-blockers in hypertension. | 1976 Jun 19 |
|
[The role of reduction of the heart rate in the favorable effect of the beta blockers on myocardial ischemia due to isoprenalin in patients with angina pectoris]. | 1977 Nov 5 |
|
Therapy of extrapyramidal side effects, with particular reference to persistent dyskinesia and lithium tremor. | 1978 |
|
Antiarrhythmic effect of oxprenolol on halothane-epinephrine and coronary ligation induced ventricular arrhythmias in beagle dogs. | 1978 Aug |
|
Two patients with schizophrenic-like psychosis after treatment with beta-adrenergic blockers. | 1979 Mar 24 |
|
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. | 1980 Jun |
|
Effect of prazosin and oxprenolol on plasma renin activity and blood pressure in patients with essential hypertension. | 1981 |
|
Mediation of renin release in essential hypertension by alpha-adrenoreceptors. | 1981 Nov-Dec |
|
Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. | 1982 |
|
Beta-adrenoreceptor antagonists and diplopia. | 1982 Oct 9 |
|
Some functional changes in experimentally induced cardiac overload. | 1983 |
|
Oxprenolol hydrochloride: pharmacology, pharmacokinetics, adverse effects and clinical efficacy. | 1983 Mar-Apr |
|
Clinical responses to oxprenolol in the elderly. | 1983 Nov 10 |
|
Increased plasma vasopressin and serum uric acid in the low renin type of essential hypertension. | 1984 |
|
Effect of oxprenolol on ventricular arrhythmias: the European Infarction Study experience. | 1985 Nov |
|
Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. | 1986 |
|
Haemodynamic, metabolic, and lymphocyte beta 2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. | 1987 |
|
Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. | 1987 Dec |
|
A nonsteady-state agonist antagonist interaction model using plasma potassium concentrations to quantify the beta-2 selectivity of beta blockers. | 1989 Apr |
|
Cardioprotection by beta-blockers: molecular and structural aspects in experimental hypertension. | 1990 |
|
Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization. | 2003 Nov-Dec |
|
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. | 2004 May |
|
A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. | 2007 Oct 16 |
Patents
Sample Use Guides
Chest pain (angina): 80-160 mg a day taken in 2 to 3 doses. The maximum daily dose is 320 mg.
High blood pressure (hypertension): 80-160 mg a day given in 2 to 3 doses. The maximum daily dose is 320 mg.
Irregular heart beats: 20-80 mg taken 2 or 3 times a day. The maximum daily dose is 240 mg.
Anxiety: The starting dose is 40 mg taken twice a day. A single dose of Trasicor (40-80 mg) may be taken for anxiety during a specific stressful situation.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6152393
Oxprenolol had biphasic actions on the rat sarcolemmal Ca2+ pump activities; the lower concentrations (1 and 10 microM) were stimulatory, but the higher concentrations (100 and 1000 microM) were inhibitory.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1483505
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
100000092814
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
DBSALT001070
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
71172
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
m8321
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
229-260-5
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
C66277
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
DTXSID5021093
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
CHEMBL546
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
6452-73-9
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
F4XSI7SNIU
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
203131
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | RxNorm | ||
|
Trasicor
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY | |||
|
SUB03578MIG
Created by
admin on Fri Dec 15 16:16:57 GMT 2023 , Edited by admin on Fri Dec 15 16:16:57 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD